The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?

This is the authors' abstract. We don't add key points for this paper.

Uncontrolled inflammation, partly related to activated macrophages, is widely recognised as an independent cause of clinical deterioration and mortality in hospitalised coronavirus disease (COVID-19) patients (Webb et al., 2020; Del Valle et al., 2020). Following the results of the RECOVERY trial and of an additional meta-analysis, corticosteroids are now recommended as a standard of care for hospitalised patients with severe and critical COVID-19 (WHO, 2020). Importantly, the benefit of this anti-inflammatory intervention has been observed with a low dose of dexamethasone, while observational studies using higher dosage of corticosteroids have not reported any favourable effect on mortality (Hasan et al., 2020).